ACTB and coronary artery disorder: Nevertheless, our findings suggested that the methylation patterns in the blood may not be sensitive to most cardiovascular medications, and thus, the methylation signatures of ACTB might have the potential to be a biomarker for the risk evaluation or early detection of CHD in the future but not for the monitoring of treatment.